BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

Innovator pharmaceutical manufacturers hope the new “phase one” U.S.-China trade deal will create a cease-fire in the stealth war on pharma IP in China. The deal, announced Dec. 13, comes at the end of a...
BioCentury | Oct 9, 2019
Politics, Policy & Law

Time to fulfill China’s promise of IP reform

Two years ago, on Oct. 8, 2017, the top bodies of the Chinese Communist Party and the Chinese government created a pathway to IP reform that promised to propel the nation into the global innovation...
BC Extra | Sep 20, 2019
Company News

Xospata poised for EU approval under accelerated assessment

EMA's CHMP recommended approval of Xospata for acute myelogenous leukemia in its September roundup. Under accelerated assessment, the agency backed Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as monotherapy for relapsed or refractory AML in...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BC Week In Review | Jul 6, 2018
Clinical News

AZ's Farxiga plus Onglyza non-inferior to Lantus in Phase IIIb for Type II diabetes

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Farxiga (Forxiga) dapagliflozin plus Onglyza saxagliptin met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 24 in a Phase IIIb trial to...
BC Extra | Feb 2, 2018
Company News

AZ partners with Chinese internet giants, reports strong China sales

AstraZeneca plc (LSE:AZN; NYSE:AZN) announced two Chinese partnerships along with its 4Q17 earnings report Friday, which showed the company's sales in the country increased 30% at constant exchange rates to $813 million for the quarter....
BC Week In Review | Dec 15, 2017
Company News

BioPharma Credit gets BMS diabetes royalties

Debt investor BioPharma Credit plc (LSE:BPCR) acquired from Royalty Pharma (New York, N.Y.) half of its royalty streams on sales of diabetes products including Onglyza saxagliptin (BMS-477118, OPC-262) and Farxiga/Forxiga dapagliflozin. Royalty Pharma acquired the...
BC Extra | Nov 9, 2017
Company News

AZ reports strong China growth in earnings

In its 3Q17 earnings, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported strong growth in the China market despite overall declining product sales. In China, sales were $723 million for the quarter, a 14% increase at constant exchange...
BC Extra | Jul 21, 2017
Preclinical News

Researchers suggest inhibiting DPP-4 could help treat colitis

In a paper published in the Journal of Pharmacology and Experimental Therapeutics , researchers from the Medical University of Lodz and the University of Gdansk showed that inhibiting dipeptidyl peptidase-4 ( DPP-4 ; CD26) could help treat...
BC Week In Review | May 26, 2017
Clinical News

CHMP recommends AZ's Komboglyze for combo treatments in Type II diabetes

EMA’s CHMP recommended expanding the label for Type II diabetes drug Komboglyze saxagliptin/metformin from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include combination treatment with other products for diabetes, including insulin, in patients inadequately controlled on metformin...
Items per page:
1 - 10 of 177